Atossa Genetics (ATOS) has become a very exciting story for investors in recent months. Our recent article provides some fundamental background information on the company. The marketplace has a growing awareness of the cautious optimism building among the families and patients who are fighting breast cancer. The FDA approved Expanded Access program trial for the first patient to receive Atossa's Endoxifen drug therapy was a measurable success in both safety and efficacy. After the FDA's due diligence was performed upon Atossa's Endoxifen drug therapy, the administration recently granted a